Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1983;25(3):223–89. https://doi.org/10.2165/00003495-198325030-00001.

Article  PubMed  Google Scholar 

Todd PA, Brogden RN. Cefotaxime. An update of its pharmacology and therapeutic use. Drugs. 1990;40(4):608–51. https://doi.org/10.2165/00003495-199040040-00008.

Article  PubMed  Google Scholar 

WHO. Model list of essential medicines. 2023. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists. Accessed 25 Sep 2023.

Arafat M, Kirchhoefer C, Mikov M, Sarfraz M, Löbenberg R. Nanosized liposomes containing bile salt: a vesicular nanocarrier for enhancing oral bioavailability of BCS class III drug. J Pharm Pharm Sci. 2017;20:305–18. https://doi.org/10.18433/J3CK88.

Article  PubMed  Google Scholar 

Esmieu F, Guibert J, Rosenkilde HC, Ho I, Le Go A. Pharmacokinetics of cefotaxime in normal human volunteers. J Antimicrob Chemother. 1980;6(Suppl A):83–92. https://doi.org/10.1093/jac/6.suppl_a.83.

Article  PubMed  Google Scholar 

Doluisio JT. Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function. Rev Infect Dis. 1982;4(Suppl):S333–45. https://doi.org/10.1093/clinids/4.supplement_2.s333.

Article  PubMed  Google Scholar 

Bergan T. Pharmacokinetic properties of the cephalosporins. Drugs. 1987;34(Suppl 2):89–104. https://doi.org/10.2165/00003495-198700342-00008.

Article  PubMed  Google Scholar 

Claforan® (Cefotaxime) Product Monograph. Sanofi-aventis Canada Inc. https://products.sanofi.ca/en/claforan.pdf. Revised November 12, 2014. Accessed 10 Apr 2023.

Reeves DS, White LO, Holt HA, Bahari D, Bywater MJ, Bax RP. Human metabolism of cefotaxime. J Antimicrob Chemother. 1980;6(Suppl A):93–101. https://doi.org/10.1093/jac/6.suppl_a.93.

Article  PubMed  Google Scholar 

Jones RN, Barry AL, Thornsberry C. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. Rev Infect Dis. 1982;4(Suppl):S366–73. https://doi.org/10.1093/clinids/4.supplement_2.s366.

Article  PubMed  Google Scholar 

Chamberlain J, Coombes JD, Dell D, Fromson JM, Ings RJ, Macdonald CM, McEwen J. Metabolism of cefotaxime in animals and man. J Antimicrob Chemother. 1980;6(Suppl A):69–78. https://doi.org/10.1093/jac/6.suppl_a.69.

Article  PubMed  Google Scholar 

Jehl F, Peter JD, Picard A, Dupeyron JP, Marescaux J, Sibilly A, Monteil H. Investigation of the biliary clearances of cefotaxime and desacetylcefotaxime by an original procedure in cholecystectomised patients. Infection. 1987;15(6):450–4. https://doi.org/10.1007/BF01647231.

Article  PubMed  Google Scholar 

Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825–92. https://doi.org/10.1007/s40262-017-0506-8.

Article  PubMed  Google Scholar 

Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23(4):791–815, vii. https://doi.org/10.1016/j.idc.2009.06.008.

Article  PubMed  PubMed Central  Google Scholar 

Fillastre JP, Leroy A, Humbert G, Godin M. Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function. J Antimicrob Chemother. 1980;6(Suppl A):103–11. https://doi.org/10.1093/jac/6.suppl_a.103.

Article  PubMed  Google Scholar 

Ohkawa M, Okasho A, Motoi I, Tokunaga S, Shoda R, Kawaguchi S, Sawaki M, Shimamura M, Hirano S, Kuroda K, Awazu S. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis. Chemotherapy. 1983;29(1):4–12. https://doi.org/10.1159/000238166.

Article  PubMed  Google Scholar 

Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802. https://doi.org/10.1016/S0140-6736(21)00519-5. (Epub 2021 Jun 24).

Article  PubMed  Google Scholar 

Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7–11. https://doi.org/10.1016/j.kisu.2021.11.003. (Epub 2022 Mar 18).

Article  PubMed  PubMed Central  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Accessed 25 Sep 2023.

Pasha M, Zamir A, Rasool MF, Saeed H, Ahmad T, Alqahtani NS, Alqahtani LS, Alqahtani F. A comprehensive physiologically based pharmacokinetic model for predicting vildagliptin pharmacokinetics: insights into dosing in renal impairment. Pharmaceuticals (Basel). 2024;17(7):924.

Article  PubMed  Google Scholar 

Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn. 2016;43(5):481–504. https://doi.org/10.1007/s10928-016-9492-y. (Epub 2016 Sep 19).

Article  PubMed  PubMed Central  Google Scholar 

Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6(5):430–40. https://doi.org/10.1016/j.apsb.2016.04.004. (Epub 2016 Jun 23).

Article  PubMed  PubMed Central  Google Scholar 

Peters SA, Dolgos H. Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them. Clin Pharmacokinet. 2019;58(11):1355–71. https://doi.org/10.1007/s40262-019-00790-0.

Article  PubMed  PubMed Central  Google Scholar 

Li Q, Guan Y, Xia C, Wu L, Zhang H, Wang Y. Physiologically-based pharmacokinetic modeling and dosing optimization of cefotaxime in preterm and term neonates. J Pharm Sci. 2024. S0022-3549(24)00086-8. (Epub ahead of print).

Glöckner WM, Höffler U, Kindler J, Peters G, Sieberth HG. Elimination kinetics of cefotaxime in patients with renal insufficiency requiring dialysis. J Antimicrob Chemother. 1980;6(Suppl A):219–23. https://doi.org/10.1093/jac/6.suppl_a.219.

Article  PubMed  Google Scholar 

Wise R, Baker S, Livingston R. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother. 1980;18(3):369–71. https://doi.org/10.1128/AAC.18.3.369.

Article  PubMed  PubMed Central  Google Scholar 

Lüthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981;20(5):567–75. https://doi.org/10.1128/AAC.20.5.567.

Article  PubMed  PubMed Central  Google Scholar 

Harding SM, Monro AJ, Thornton JE, Ayrton J, Hogg MI. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J Antimicrob Chemother. 1981;8(Suppl B):263–72. https://doi.org/10.1093/jac/8.suppl_b.263.

Article  PubMed  Google Scholar 

Kemmerich B, Lode H, Belmega G, Jendroschek T, Borner K, Koeppe P. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother. 1983;23(3):429–34. https://doi.org/10.1128/AAC.23.3.429.

Article  PubMed  PubMed Central  Google Scholar 

Ings RM, Reeves DS, White LO, Bax RP, Bywater MJ, Holt HA. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. J Pharmacokinet Biopharm. 1985;13(2):121–42. https://doi.org/10.1007/BF01059394.

Article  PubMed  Google Scholar 

Hary L, Andrejak M, Leleu S, Orfila J, Capron JP. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol. 1989;36(6):613–6. https://doi.org/10.1007/BF00637745.

Article  PubMed  Google Scholar 

Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev Infect Dis. 1982;4(Suppl):S379–91. https://doi.org/10.1093/clinids/4.supplement_2.s379.

Article  PubMed  Google Scholar 

Matzke GR, Abraham PA, Halstenson CE, Keane WF. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther. 1985;38(1):31–6. https://doi.org/10.1038/clpt.1985.130.

Article  PubMed  Google Scholar